CCCC Q3 2022 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-20.5% YoY

Gross Profit

-$23M-339.2% margin

Operating Income

-$32M-481.0% margin

Net Income

-$32M-473.2% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-51.2%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$461M

Total Liabilities

$143M

Stockholders' Equity

$318M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$9M	-20.5%
Gross Profit	-$23M	-$16M	-45.0%
Operating Income	-$32M	-$24M	-33.9%
Net Income	-$32M	-$25M	-29.5%